InterCure Ltd. (NASDAQ:INCR) finalized a NIS 230 million, or approximately $77 million, settlement with Israeli authorities covering indirect damages from the October 7, 2023 attacks and subsequent war. The more relevant figure for investors is approximately $43 million.
The $77 million represents aggregate compensation rather than a new cash payment. InterCure Ltd. (NASDAQ:INCR) previously received NIS 101 million, or approximately $34 million, in advances related to the claim. Subtracting those advances from the settlement produces NIS 129 million, or approximately $43 million, of implied remaining gross compensation.
InterCure Ltd. (NASDAQ:INCR) did not disclose when that balance would be paid or what the net cash receipt would be after any applicable adjustments. The calculation therefore measures the implied gross amount remaining under the settlement, not immediate liquidity.
The amount is nevertheless material compared with the company's financial position. InterCure Ltd. (NASDAQ:INCR) reported NIS 49 million in cash on hand as of December 31, 2025, including restricted cash. The implied NIS 129 million balance is approximately 2.6 times that historical figure. InterCure Ltd. (NASDAQ:INCR) also generated NIS 17 million in operating cash flow during 2025, although it recorded a NIS 37 million net loss.
The settlement gives InterCure Ltd. (NASDAQ:INCR) a defined compensation amount after nearly three years of uncertainty. The company intends to use its strengthened financial position to accelerate rehabilitation of Canndoc's Nir Oz cultivation and production facility, which was severely damaged during the October 2023 attacks.
#approximately
The $77 million represents aggregate compensation rather than a new cash payment. InterCure Ltd. (NASDAQ:INCR) previously received NIS 101 million, or approximately $34 million, in advances related to the claim. Subtracting those advances from the settlement produces NIS 129 million, or approximately $43 million, of implied remaining gross compensation.
InterCure Ltd. (NASDAQ:INCR) did not disclose when that balance would be paid or what the net cash receipt would be after any applicable adjustments. The calculation therefore measures the implied gross amount remaining under the settlement, not immediate liquidity.
The amount is nevertheless material compared with the company's financial position. InterCure Ltd. (NASDAQ:INCR) reported NIS 49 million in cash on hand as of December 31, 2025, including restricted cash. The implied NIS 129 million balance is approximately 2.6 times that historical figure. InterCure Ltd. (NASDAQ:INCR) also generated NIS 17 million in operating cash flow during 2025, although it recorded a NIS 37 million net loss.
The settlement gives InterCure Ltd. (NASDAQ:INCR) a defined compensation amount after nearly three years of uncertainty. The company intends to use its strengthened financial position to accelerate rehabilitation of Canndoc's Nir Oz cultivation and production facility, which was severely damaged during the October 2023 attacks.
#approximately
2 days ago
